Weekly Methotrexate Increased Antithyroid-Drug Withdrawal in Graves Disease
In an open-label Graves disease RCT, methotrexate 10 mg weekly added to methimazole increased treatment withdrawal at 18 months, but remains investigational.
Hormone Insight
Evidence summaries in diabetes, endocrinology, and metabolism for clinicians who need the key data fast.
Latest Evidence
View all PICO summaries
Oral Agents Did Not Match Insulin for Gestational Diabetes Outcomes
In gestational diabetes requiring medication, metformin-first oral therapy with glyburide rescue did not prove noninferior to insulin for preventing large-for-gestational-age birth.
Zoledronate Every 5 Years Reduced Vertebral Fractures in Early Postmenopausal Women
In early postmenopausal women aged 50 to 60 years, zoledronate at baseline and 5 years reduced 10-year morphometric vertebral fractures from 11.1% to 6.3%.
Dapagliflozin Plus Calorie Restriction Increased Type 2 Diabetes Remission in Early Disease
In overweight or obese adults with early type 2 diabetes, dapagliflozin added to calorie restriction increased 12-month remission from 28% to 44%.
IoN Trial: Radioiodine Could Be Avoided After Surgery for Low-Risk Thyroid Cancer
In the IoN non-inferiority RCT, omitting postoperative radioiodine after total thyroidectomy produced 5-year recurrence-free survival of 97.9% versus 96.3% with ablation in selected low-risk thyroid cancer.
REDEFINE 1: CagriSema Produced 20.4% Weight Loss in Adults Without Diabetes
In REDEFINE 1, once-weekly cagrilintide-semaglutide produced 20.4% mean weight loss at 68 weeks versus 3.0% with placebo in adults with overweight or obesity without diabetes.
Automated Insulin Delivery Improved HbA1c and Time in Range in Type 2 Diabetes
In insulin-treated type 2 diabetes, automated insulin delivery reduced HbA1c by an adjusted 0.6 percentage points and increased time in range by 14 points versus CGM with usual insulin delivery.
CONFIDENCE: Finerenone Plus Empagliflozin Reduced Albuminuria More Than Either Drug Alone
In CKD with type 2 diabetes and albuminuria, simultaneous finerenone plus empagliflozin reduced UACR more than either treatment alone at 180 days, without unexpected safety findings.